Patient demographics and in vivo/in vitro responses to dexamethasone
| Xenograft . | Age at diagnosis, (month)/sex . | Cytogenetics . | CR1 duration (months) . | Current clinical status . | In vitro IC50 . | In vivo LGD (days) . | In vitro stratification . | In vivo stratification . |
|---|---|---|---|---|---|---|---|---|
| ALL-28 | 20/M | Hyperdiploid | +94 | CR1 | >10 µM | ND | Resistant | ND |
| ALL-50 | 131/M | normal | 30 | DOD | >10 µM | 21.1 | Resistant | Resistant |
| ALL-55 | 176/M | t(9;22) | +36 | CR1 | >10 µM | 30.7 | Resistant | Resistant |
| ALL-56 | 120/M | t(9;22) | 55 | CR2 | 9.0 nM | 4.4 | Sensitive | Resistant |
| ALL-57 | 72/F | t(1;19) | +27 | CR1 | >10 µM | 7.5 | Resistant | Resistant |
| ALL-26 | 43/F | t(12;21) | +96 | CR1 | 1.9 nM | 70.0 | Sensitive | Sensitive |
| ALL-51 | 19/M | dic(7;9) | +92 | CR1 | >10 µM | 69.7 | Resistant | Sensitive |
| ALL-52 | 138/M | t(7;15) | +80 | CR1 | 142 nM | 67.0 | Sensitive | Sensitive |
| ALL-53 | 87/M | t(12;21) | +102 | CR1 | 1.0 nM | ND | Sensitive | ND |
| ALL-54 | 89/M | normal | +93 | CR1 | 59 nM | 46.3 | Sensitive | Sensitive |
| Xenograft . | Age at diagnosis, (month)/sex . | Cytogenetics . | CR1 duration (months) . | Current clinical status . | In vitro IC50 . | In vivo LGD (days) . | In vitro stratification . | In vivo stratification . |
|---|---|---|---|---|---|---|---|---|
| ALL-28 | 20/M | Hyperdiploid | +94 | CR1 | >10 µM | ND | Resistant | ND |
| ALL-50 | 131/M | normal | 30 | DOD | >10 µM | 21.1 | Resistant | Resistant |
| ALL-55 | 176/M | t(9;22) | +36 | CR1 | >10 µM | 30.7 | Resistant | Resistant |
| ALL-56 | 120/M | t(9;22) | 55 | CR2 | 9.0 nM | 4.4 | Sensitive | Resistant |
| ALL-57 | 72/F | t(1;19) | +27 | CR1 | >10 µM | 7.5 | Resistant | Resistant |
| ALL-26 | 43/F | t(12;21) | +96 | CR1 | 1.9 nM | 70.0 | Sensitive | Sensitive |
| ALL-51 | 19/M | dic(7;9) | +92 | CR1 | >10 µM | 69.7 | Resistant | Sensitive |
| ALL-52 | 138/M | t(7;15) | +80 | CR1 | 142 nM | 67.0 | Sensitive | Sensitive |
| ALL-53 | 87/M | t(12;21) | +102 | CR1 | 1.0 nM | ND | Sensitive | ND |
| ALL-54 | 89/M | normal | +93 | CR1 | 59 nM | 46.3 | Sensitive | Sensitive |
CR1, first complete remission; CR2, second complete remission; DOD, dead of disease; LGD, leukemia growth delay (days); ND, not determined; resistant, IC50 > 1 μM, LGD < 40 days; sensitive, IC50 < 1 µM, LGD > 40 days; +, no event.